

# KEY INFORMATION DOCUMENT

Purpose: This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## PRODUCT

### Kieger Impact Healthcare Fund - Class B EUR (Acc)

A Sub-Fund of Kieger UCITS Fund

ISIN: LU2488093456

#### Manufacturer:

Name: FundRock Management Company S.A.  
Contact Details: FundRock Management Company S.A. Airport Center Building 5, Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg  
Call (+352) 26 3456 1 for more information  
Website: [www.fundrock.com](http://www.fundrock.com)  
Competent Authority: Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising FundRock Management Company S.A. in relation to this Key Information Document. Kieger UCITS Fund is authorised in Luxembourg and regulated by Commission de Surveillance du Secteur Financier (CSSF).  
Date of production: 31-01-2025

## WHAT IS THIS PRODUCT?

**Type:** This product is a share of an investment company qualifying as an undertaking for collective investment in transferable securities (UCITS).

**Term:** This product has no maturity date. However, the Board of Directors may decide to close the product under certain circumstances.

**Objectives:** The Sub-Fund aims to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies of issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realization of the healthcare related United Nations Sustainable Development Goals ("SDGs"). There is no guarantee that the Sub-Fund will achieve a positive return over this, or any other, period and you may not get back the original amount you invested.

The Sub-Fund will invest, directly or indirectly, at least 80% of its net assets in equity and equity-type securities (such as Depositary Receipts, American Depositary Receipts, Global Depositary Receipts, etc.) of issuers worldwide (including Emerging Markets) in the healthcare and healthcare related industry. The Sub-Fund is not constrained as to currency of denomination (which must be freely convertible), market capitalization or geography.

In addition, the Sub-Fund may invest up to 10% of its net assets in fixed income securities denominated in any freely convertible currency of issuers worldwide having at least an Investment Grade rating, up to 10% of its net assets in Money Market Instruments of issuers worldwide having at least an Investment Grade rating and denominated in any freely convertible currency of denomination.

The Sub-Fund may invest in other UCITS or other collective investment funds (whether or not they are exchange traded), provided that such UCITS or other collective investment funds principally invest in the types of instruments mentioned above.

More than 50% of the asset value of each Sub-Fund will be invested on an ongoing basis in equity participations.

On a temporary basis and for defensive purposes, the Sub-Fund may also hold up to 100% of its net assets in liquid assets.

**Derivatives Policy:** For hedging and investment purposes, the Sub-Fund may use all types of financial derivative instruments traded on a Regulated Market and/or OTC (Over the Counter).

**Benchmark:** The Sub-Fund is actively managed by reference to the MSCI World Health Care Net Index (the "Benchmark") for the purposes of performance measurement. There are no restrictions on the extent to which the Sub-Fund's holdings may deviate from the Benchmark.

**SFDR:** The Sub-Fund meets the criteria in Article 9 of the Sustainable Finance Disclosure Regulation (Regulation EU/2019/2088) to qualify as a financial product that has sustainable investment as its objective. More information on this product's sustainability factors can be found in the Prospectus and on the following website: [www.kieger.com](http://www.kieger.com).

**Distribution Policy:** Your shares will be accumulating. Income from investments in the Fund will be re-invested and therefore rolled up into the value of your shares.

The Sub-Fund launched on 01 October 2020. The Share Class launched on 06 July 2023.


The currency of the Fund is USD, the currency of this product is EUR.

**Intended retail investor:** "B" shares may be offered in certain limited circumstances for distribution in certain countries and through distributors, platforms and/or broker/dealers who have separate fee arrangements with their clients. An investor should be willing to invest for the medium to long term (five years) to gain access to a portfolio managed in accordance with an investment objective and policy which targets capital growth and income from equities. Investors must be prepared to accept fluctuations in the value of capital including possible capital loss and accept the risks of investing in equity markets. Investors should understand the risks involved, including the risk of losing all capital invested and must evaluate. The Company's objective and risks in terms of whether they are consistent with their own investment goals and risk tolerances.

**Depository:** Northern Trust Global Services SE

## WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

## Risks



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity to pay you.

**Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

Investors shall note that the product may be exposed to risks such as risk associated with investing in emerging markets, the value of equities and equity-related securities, currency risk, counterparty risk, active management, credit risk, derivatives Instruments, hedging risk, Risks associated with Depositary Receipts and Environmental, Social and Governance Risk (ESG). For further details of the Fund's risks please see the Prospectus.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

## Performance scenarios

**What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.**

**The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 10 years. Markets could develop very differently in the future.**

The before-mentioned calculations were performed using benchmark MSCI World Healthcare Net TR Index.

Recommended holding period		5 years	
Example Investment		EUR 10 000	
Scenarios		If you exit after 1 Year	If you exit after 5 years (recommended holding period)
Minimum	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
Stress	<b>What you might get back after costs</b>	<b>1 990 EUR</b>	<b>1 590 EUR</b>
	Average return each year	-80.1 %	-30.7 %
Unfavourable	<b>What you might get back after costs</b>	<b>7 520 EUR</b>	<b>7 500 EUR</b>
	Average return each year	-24.8 %	-5.6 %
Moderate	<b>What you might get back after costs</b>	<b>10 270 EUR</b>	<b>12 670 EUR</b>
	Average return each year	2.7 %	4.9 %
Favourable	<b>What you might get back after costs</b>	<b>12 320 EUR</b>	<b>16 670 EUR</b>
	Average return each year	23.2 %	10.8 %

**Unfavourable scenario:** This type of scenario occurred when investing between 08/2021 and 12/2024.

**Moderate scenario:** This type of scenario occurred when investing between 01/2018 and 01/2023.

**Favourable scenario:** This type of scenario occurred when investing between 10/2016 and 10/2021.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

## WHAT HAPPENS IF FundRock Management Company S.A. IS UNABLE TO PAY OUT?

The Management Company is responsible for administration and management of the Fund, and does not typically hold assets of the Fund (assets that can be held by a depositary are, in line with applicable regulations, held with a depositary in its custody network). The Management Company, as the PRIIPs manufacturer has no obligation to pay out since the product design does not contemplate any such payment being made. However, investors may suffer loss if the Fund or the depositary is unable to pay out. There is no compensation or guarantee scheme in place which may offset, all or any, of this loss.

## WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario,
- EUR 10 000 is invested.

Example Investment 10 000 EUR		
Scenarios	If you exit after 1 Year	If you exit after 5 years (recommended holding period)
Total Costs	186 EUR	1 160 EUR
Annual Cost impact (*)	1.9%	2.0% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your

average return per year is projected to be 6.8 % before costs and 4.9 % after costs.

## Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
<b>Entry costs</b>	We do not charge an entry fee for this product.	<b>0 EUR</b>
<b>Exit costs</b>	We do not charge an exit fee for this product.	<b>0 EUR</b>
Ongoing costs taken each year		
<b>Management fees and other administrative or operating costs</b>	1.6% of the value of your investment per year. This is an estimate based on actual costs over the last year.	<b>159 EUR</b>
<b>Transaction costs</b>	0.3% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	<b>27 EUR</b>
Incidental costs taken under specific conditions		
<b>Performance fees</b>	There is no performance fee or carried interest for this product.	<b>N/A</b>

## HOW LONG SHOULD I HOLD AND CAN I TAKE MY MONEY OUT EARLY?

### Recommended holding period: 5 Years

You should be prepared to stay invested for 5 years. However, you can redeem your investment without penalty at any time during this time, or hold the investment longer. Redemptions are possible any day on which banks in Luxembourg and Zürich are open for business except for 24 December. In exceptional circumstances, your right to request the redemption of your investment may be limited or suspended.

## HOW CAN I COMPLAIN?

Complaints about the behaviour of the person who advised you on the product or sold it to you, should be addressed directly to that person. Complaints about the product or the behaviour of the manufacturer of this product should be directed to the following address:

Postal address: FundRock Management Company S.A., Airport Center Building 5, Heienhaff, L-1736 Senningerberg, Grand Duchy of Luxembourg.

E-mail: [FRMC\\_qualitycare@fundrock.com](mailto:FRMC_qualitycare@fundrock.com)

Website: <https://www.fundrock.com/policies-and-compliance/complaints-policy/>

In all cases, the complainant must clearly indicate his/her contact details (name, address, phone number or email address) and provide a brief explanation of the claim.

## OTHER RELEVANT INFORMATION

**Conversion right:** Shareholders are entitled (subject to certain restrictions) to convert all or part of their shares in a class for shares of another class within the same Fund or to switch shares for another of the same or another class within a different Fund of the Company. The investor can obtain information about how to convert in the prospectus of the fund.

**Segregation:** Under Luxembourg law, the UCITS has segregated liability between its sub-funds (i. e. the UCITS assets will not be used to discharge the liabilities of other Sub-Funds within the umbrella). In addition, the Sub-Fund's assets are held separately from the assets of other sub-funds.

**Additional information:** Copies of the latest prospectus, annual report, semi-annual report (all available in English), and the latest Net Asset Value per Share, are available free of charge at the registered office of the Management Company, FundRock Management Company S.A. in its offices at H2O building, 33 rue de Gasperich, L-5826 Hesperange, Luxembourg and/or on the following website <https://kieger.com/>.

**Past performance and previous performance scenarios:** The cost, performance and risk calculations included in this key information document follow the methodology prescribed by EU rules. Note that the performance scenarios calculated above are derived exclusively from the past performance of the Fund's share price/ suitable benchmark and that past performance is not a guide to future returns. Therefore, your investment may be at risk and you may not get back the returns illustrated. Investors should not base their investment decisions solely upon the scenarios shown.

Any past performance data presented will be for up to 10 calendar years from the date of the launch of a share class. No performance data will be presented for a share class that does not yet have performance data for one complete calendar year as there would be insufficient data to provide a useful indication of past performance to retail investors.

**Swiss Disclosure:** The state of the origin of the sub fund is Luxembourg. In Switzerland, the representative is ACOLIN Fund Services AG, Leutschenbachstrasse 50, CH-8050, Zurich, whilst the paying agent is Banque Cantonale de Geneve, 17, quai de l'Ile, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi annual reports may be obtained free of charge from the representative. The Swiss ombudsman is Verein Ombudsstelle Finanzdienstleister (OFD), Bleicherweg 10, CH-8002 Zurich.

**Performance scenarios:** You can find previous performance scenarios updated on a monthly basis at <https://priips-scenarios.com/kieger/LU2488093456/en/>

**Past performance:** You can download the past performance over the last 1 years from our website at <https://priips-performance-chart.com/kieger/LU2488093456/en/>